Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2024-04-18

FDA Approved: ALECENSA — Supplemental Application (Genentech, Inc.)

View source ↗

Summary

FDA approves a supplemental application for Alecensa (alectinib hydrochloride) submitted by Genentech, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Alecensa (alectinib)

Snippet

SUPPL AP for ALECENSA (ALECTINIB HYDROCHLORIDE)